Bromodomain Inhibitor, (+)-JQ1

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Bromodomain Inhibitor, (+)-JQ1 is a potent and highly specific inhibitor for the BET (bromodomain and extra-terminal) family of bromodomains. (+)-JQ1 binds to BRD4 bromodomains 1 and 2 with Kd values of ~ 50 and 90 nM, respectively. The binding is competitive with acetyl lysine. (+)-JQ1 can be a useful chemical probe to investigate the role of BET bromodomains in the transcriptional regulation of oncogenesis.
    JQ1 exhibited strong dose-and time- dependent inhibition of BRDT and could significantly diminish the activity of a close structural relative of BRDT. A close look at JQ1 bound BRDT confirmed that the acetyl-lysine recognition site of BRDT was blocked. [1]
    JQ1 does not produce sedative or anxiolytic effects and is instead a potent and selective inhibitor of the bromodomain testis-specific protein BRDT [2], which is essential for chromatin remodeling during spermatogenesis. By blocking BRDT, JQ1 effectively blocks the production of sperm in the testes and consequently produces effective contraception, without the negative side effects associated with previously researched hormonal contraceptives for men.
    
    1. Matzuk, Martin M., et al. "Small-molecule inhibition of BRDT for male contraception." Cell 150.4 (2012): 673-684. 2. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T. et al. (2010). "Selective inhibition of BET bromodomains". Nature 468 (7327): 1067–1073.
- Properties
  - Alternative Name
    
    (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate
    
    CAS Number
    
    1268524-70-4
    
    Molecular Formula
    
    C23H25ClN4O2S
    
    Molecular Weight
    
    456.99
    
    Purity
    
    99.84%
    
    Solubility
    
    ≥22.85 mg/mL in DMSO; insoluble in H2O; ≥55.6 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Amjad Ali, Jasmin Shafarin, et al. "Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer." Int J Biol Sci. 2021 Oct 25;17(15):4474-4492. PMID:34803511
    2. Victor Cy Mak, Xinran Li, et al. "p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair." Neoplasia. 2021 Jul;23(7):718-730. PMID:34144267
    3. Lars Pache, Matthew D. Marsden, et al. "Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo." Cell Rep Med. 2020 Jun 23;1(3):100037. PMID:33205060
    4. Niklas Remke, Savita Bisht, et al. "Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses." Cancer Immunol Immunother. 2020 Jul 10. PMID:32651619
    5. Xiang Y, Tanaka Y, et al. "Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons." Mol Cell. 2020;79(1):84-98.e9. PMID:32526163
    6. Wu SY, Lee CF, et al. "Opposing Functions of BRD4 Isoforms in Breast Cancer." Mol Cell. 2020;78(6):1114-1132.e10. PMID:32446320
    7. Xu Y, Wu Y, et al. "A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2." Cell Rep. 2019 Dec 10;29(11):3435-3447.e4. PMID:31825827
    8. Huang Y, Mouttet B, et al. "The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability." Cancer Cell. 2019 Nov 1. pii: S1535-6108(19)30478-7. PMID:31735627
    9. Zhu X, Zhang T, et al. "A super-enhancer controls TGF- β signaling in pancreatic cancer through downregulation of TGFBR2." Cell Signal. 2019;109470. PMID:31730895
    10. Ha SD, Cho W, et al. "The transcription factor PU.1 mediates enhancer-promoter looping that is required for IL-1β eRNA and mRNA transcription in mouse melanoma and macrophage cell lines." J Biol Chem. 2019 Nov 15;294(46):17487-17500. PMID:31586032
    11. Hongtao Shen, Jing Li, et al. "BRD2 regulation of sigma-2 receptor expression upon cytosolic cholesterol deprivation." bioRxiv. 2019 August 28.
    12. Kurimchak AM, Shelton C, et al. "Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer." Mol Cancer Res. 2019 Aug;17(8):1721-1734. PMID:31043489
    13. Liu K, Zhou Z, et al. "JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression." Cell Biol Int. 2019 Jun;43(6):642-650. PMID:30958600
    14. Kushani Shah, Robert H Whitaker, et al. "Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth." bioRxiv. 2019 February 19.
    15. Kim DU, Nam J, et al. "Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD-1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway." Oncol Lett. 2019 Mar;17(3):3589-3598. PMID:30867802
    16. Talha Ijaz. "Fibroblasts: Key Cells in Inflammation and Fibrosis." University of Texas Medical Branch.May, 2018.
    17. Henry KE, Dacek MM, et al. "A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer." Clin Cancer Res. 2018 Sep 18. pii: clincanres.1485.2018. PMID:30228208
    18. Zhang P, He F, et al. "Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy." J Clin Invest. 2018 Oct 29. pii: 121366. PMID:30226831
    19. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600. PMID:30190514
    20. Deng W, Clipson A, et al."Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression." Transl Oncol. 2018 Jul 25;11(5):1147-1154. PMID:30055346
    21. Kim SR, Lewis JM, et al. "BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition." Oncotarget.2018 Jun 26;9(49):29193-29207. PMID:30018745
    22. Li N, Yang L, et al. "BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc." Cell Death Dis. 2018 Jul 9;9(7):761. PMID:29988031
    23. Wang B, Chen G, et al. "A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters." Biomaterials. 2018 Jun 18;178:293-301. PMID:29958152
    24. Pulikkan JA, Hegde M, et al."CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia." Cell. 2018 Jun 28;174(1):172-186.e21. PMID:29958106
    25. Leonard B, Brand TM, et al. "BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC." Cancer Res. 2018 May 23. pii:canres.0459.2018. PMID:29792310
    26. Yang R, Wu Y, et al. "A super-enhancer maintains homeostatic expression of Regnase-1." Gene. 2018 May 16. pii: S0378-1119(18)30542-0. PMID:29777912
    27. Chen D, Zhao Z, et al. "Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma." Bone Res. 2018 Apr 4;6:11. PMID:29644114
    28. Russell JO, Ko S, et al. "Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration." Am J Pathol. 2018 Jun;188(6):1389-1405. PMID:29545201
    29. Tonouchi E, Gen Y, et al."miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequenceand downregulates the BRD4-NUT fusion oncoprotein." Sci Rep. 2018 Mar 14;8(1):4482. PMID:29540837
    30. Sun C, Yin J, et al. "BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency." Cancer Cell. 2018 Mar 12;33(3):401-416.e8. PMID:29533782
    31. Huang F, Shao W, et al. "Bromodomian-containing protein 4-independent transcriptional activation by autoimmune regulator (AIRE) and NF-κB."J Biol Chem. 2018 Feb 20. pii: jbc.RA117.001518. PMID:29463681
    32. Cheng X, Zhou B, et al. "One new indolocarbazole alkaloid from the Streptomyces sp. A22." Nat Prod Res. 2018 Jan 22:1-6. PMID:29355042
    33. Singleton KR, Crawford L, et al. "Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence." Cell Rep. 2017 Dec 5;21(10):2796-2812. PMID:29212027
    34. Benito E, Ramachandran B, et al. "The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice." Transl Psychiatry. 2017 Sep 26;7(9):e1239. PMID:28949335
    35. Henry KE, Dilling TR, et al."Noninvasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared with (18)F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer." J Nucl Med. 2018 Jan;59(1):51-57. PMID:28848040
    36. Zhou F, Shimoda M, et al. "Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma." Mol Cancer Ther.2017 Nov;16(11):2627-2638. PMID:28847988
    37. Korb E, Herre M, et al. "Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition." Cell. 2017 Aug 12. PMID:28823556
    38. Cheng X, Yu L, et al. "New brefeldins and penialidins from marine fungus Penicillium janthinellum DT-F29." Nat Prod Res. 2017 Jul 19:1-5. PMID:28722499
    39. Alfonso-Dunn R, Turner AW, et al. "Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency." Cell Host Microbe. 2017 Apr 12;21(4):507-517.e5. PMID:28407486
    40. Li J, Zhao L, et al. "Epigenetic intervention with a BET inhibitor ameliorates acute retinal ganglion cell death in mice." Mol Vis. 2017 Mar 21;23:149-159. eCollection 2017. PMID:28356707
    41. A Figge D, Standaert DG. "Dysregulation of BET proteins in levodopa-induced dyskinesia." Neurobiol Dis. 2017 Jun;102:125-132. PMID:28286180
    42. Ijaz T, Jamaluddin M, et al. "Coordinate activities of BRD4 and CDK9 in the transcriptional elongation complex are required for TGFβ-induced Nox4 expression and myofibroblast transdifferentiation." Cell Death Dis. 2017 Feb 9;8(2):e2606. PMID:28182006
    43. Liyan Yu, Wanjing Ding,et al. "Induction of cryptic bioactive 2,5-diketopiperazines in fungus Penicillium sp. DT-F29 by microbial co-culture." Tetrahedron. 2017 Jan.
    44. Rulina AV, Mittler F, et al. "Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity." Cell Death Dis. 2016 Dec 1;7(12):e2505. PMID:27906189
    45. Chatterjee N, Tian M, et al. "Keap1-Independent Regulation of Nrf2 Activity by Protein Acetylation and a BET Bromodomain Protein." PLoS Genet. 2016 May 27;12(5):e1006072. PMID:27233051
    46. Verbist KC, Guy CS, et al. "Metabolic maintenance of cell asymmetry following division in activated T lymphocytes." Nature. 2016 Apr 21;532(7599):389-93 PMID:27064903
    47. Alonso, Victoria Lucia, et al. "Overexpression of bromodomain factor 3 in Trypanosoma cruzi (TcBDF3) affects differentiation of the parasite and protects it against bromodomain inhibitors." FEBS Journal (2016). PMID:27007774
    48. Peeters, Janneke GC, et al. "Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression." Cell reports (2015). PMID:26387944
    49. Korb, Erica, et al. "BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice." Nature Neuroscience (2015). PMID:26301327
    50. Li V C, Kirschner M W. "Molecular ties between the cell cycle and differentiation in embryonic stem cells[J]." PNAS, 2014: 201408638.

Bromodomain Inhibitor, (+)-JQ1

Background

We Also Recommend

Lomeguatrib

RG 108

UNC0638